compareglp-1

A comparison studio
Independent editorial information · not individual medical advice

Commercial pages may contain paid referral links. Compare the full payment terms and licensed-care details before enrollment.

Provider Verdicts

Async-Only vs. Video-Required Providers: Speed, Cost, and Care Quality Compared

Price verification — October 26, 2026

Some examples and provider price illustrations in this article are estimates, not guaranteed checkout quotes.

  • Wegovy (semaglutide): Wegovy tablet: $149/30 tablets at 1.5 mg, $199 at 4 mg (a temporary $149 4 mg offer may apply), and $299 at 9 mg or 25 mg. Wegovy injection: eligible new patients may pay $199 per 28-day fill for the first two fills at 0.25 or 0.5 mg through Dec. 31, 2026, then generally $349 for standard pen doses. Eligibility and dosage restrictions apply. Official source
  • Zepbound (tirzepatide): LillyDirect self-pay: 2.5 mg starts at $299/28 days, 5 mg at $399, and 7.5 mg and above at $449 only with qualifying 45-day refill timing. Higher-dose prices can be higher when those conditions are not met. Supplies may cost extra. Official source
  • Clinical program fees: Ivím lists a $74.99/month membership with medication billed separately. Sesame lists care from $59/month on a 12-month commitment; month-to-month costs more, and medication is separate. These are care fees, not all-inclusive drug prices. Official source
  • Sesame annual-commitment terms: Official source.

These are manufacturer self-pay or listed care-fee examples, not one all-inclusive price or guaranteed prescription. Insurers, clinical visits, pharmacy choice, dosage, supplies, refill conditions and geography can change the amount due.

Updated August 6, 2026 · CompareGLP-1 Editorial

Behind every GLP-1 provider comparison lurks a structural choice: platforms built on asynchronous questionnaire review versus those requiring a live video visit. It shapes everything — speed, price, and the depth of medicine you receive. We compared the models head-to-head across four dimensions.

Key Takeaways

  • Speed: async wins by days — commonly 24–72 hours intake-to-prescription vs. scheduling lead times for video.
  • Cost: async's lower clinician-time overhead shows up in lower prices, all else equal.
  • Care depth: video wins for complex histories — real-time dialogue catches what checkboxes miss.
  • Verdict: simple history → async and save; diabetes, polypharmacy, or GI history → buy the video visit. State law may decide for you anyway.

Round 1: Speed

Async's pipeline — intake, queue, clinician review, e-prescribe — routinely completes in 1–3 days. Video adds scheduling: finding a slot, waiting for it, attending it. For a straightforward patient, async wins this round by 3–7 calendar days. Async, clearly.

Round 2: Cost

A 20-minute live visit costs more clinician time than an async chart review, and pricing reflects it across the market. The gap isn't enormous — and some video-model programs bundle it invisibly — but the structural edge is real. Async on points.

Round 3: Screening and Care Depth

Here the fight reverses. A live clinician probes in real time: the follow-up question about your pancreatitis episode, the medication you forgot until asked twice, the hesitation in your answer about eating history. Checkbox intakes — even conscientious ones — can't chase ambiguity. For a patient with diabetes medications, a long med list, GI history, or psychiatric complexity, that dialogue is where safety lives. Video, decisively, for complex patients; a quality async review is adequate for simple ones.

Round 4: Ongoing Care

Model matters less than culture here — an async platform with fast, substantive portal messaging beats a video platform whose next appointment is three weeks out. Test either the same way: send a clinical question, time the substance of the reply. Draw; judge the provider, not the model.

The Regulatory Referee

Several states require real-time interaction to establish care, so the same national brand may be async in one state and video-first in the next. Your address, entered at intake, may cast the deciding vote in this whole comparison.

Verdicts by Profile

ProfilePickWhy
Healthy, no daily meds, clear-cut BMIAsyncDays faster, cheaper, nothing for video to add
Type 2 diabetes / insulin / sulfonylureasVideoReal-time dose-coordination planning
Long medication list or GI historyVideoDialogue catches interactions checkboxes miss
Established patient switching providersAsyncYou need continuity, not re-discovery
Shift worker / chaotic scheduleAsyncNo appointment friction at all

Strong Programs on Each Side

Embody

Injectable semaglutide — $149 first month

Our lead injectable pick: physician-supervised semaglutide with clean flat pricing after the intro month.

Compounded medications are not FDA-approved.

Care Bare Rx

Injectable + oral options in intake

Both pathways available depending on clinical review.

Compounded medications are not FDA-approved.

Try Gala GLP-1 instead

Sesame Care

Brand-name only — Rybelsus and oral Wegovy from $149–$299/mo

Brand-name FDA-approved medications only — the comparison anchor for every compounded price on this site.

Visit Sesame Care

Final verdict: async is the right machine for simple cases and the wrong shortcut for complex ones. Know which case you are before the market decides for you.

Affiliate disclosure: Links marked "Paid link" are affiliate links. We may earn a commission if you sign up through them, at no extra cost to you. This supports our independent research.

Compounded medication notice: Compounded medications are not FDA-approved. The FDA does not verify the safety, effectiveness, or quality of compounded drugs before they are marketed. Brand-name alternatives (Wegovy, Ozempic, Zepbound, Rybelsus) are FDA-approved.

Medical disclaimer: This article is for informational purposes only and is not medical advice. GLP-1 medications are prescription drugs. Always consult a licensed healthcare provider about diagnosis, treatment, dosing, and whether these medications are appropriate for you.